Drug Use Evaluation on Type 2 Diabetes Mellitus and Diabetic Nephropathy Inpatients in One of Hospitals in Tasikmalaya

Najiah R. Nisa, Muharram Priatna, Yedy P. Sukmawan

Abstract


Type 2 Diabetes mellitus (T2DM) is a degenerative disease and approximately 50% of patients with diabetes mellitus (DM) of more than 20 years’ duration also have diabetic nephropathy (DN). T2DM accounts for significant morbidity and mortality, however appropriate treatment can reduce the events. The objective of the study was to evaluate of drug use in inpatient T2DM and DN. This was a cross-sectional study with concurrent data retrieval on T2DM and DN inpatients in the period of March–June 2017 in one of hospitals in Taskimalaya, Indonesia. Forty-six patients were included in the study, of which 25 patients had T2DM and 21 had DN. The result of this study showed that appropriateness of drug selection reached 100% and 85.6% in T2DM and DN inpatients, respectively. Inappropriateness of drugs selection includes selection of ketorolac, ranitidine, folic acid, amlodipine and potassium containing drugs. Doses accuracy of T2DM patients reached 100% and of DN inpatients reached 92.1%. The inaccuracy of doses was due to the lack of dose adjustment to estimated glomerulus filtration rate (eGFR) level in each patient. Drugs interaction analysis showed a potential drug interaction on DN and T2DM which devided into major (13.8%; 7.2%), moderate (64.1%; 58%) and minor (22,1%; 34.8%). Based on the result, it is found an inappropriate drug selection and an inaccuracy of dose in DN patients, and a high percentage of drugs interaction on moderate classification in both diseases. It is necessary to optimize the role of pharmacist as a part of the healthcare team in the patient’s room to apply medication therapy management.

Keywords: Drugs use evaluation, type 2 diabetes mellitus, diabetic nephropathy


Evaluasi Penggunaan Obat pada Pasien Rawat Inap Diabetes Melitus Tipe 2 dan Nefropati Diabetik di Salah Satu Rumah Sakit di Tasikmalaya

Abstrak
Diabetes melitus tipe 2 (DMT2) merupakan penyakit degeneratif dan sekitar 50% dari pasien yang telah menderita penyakit diabetes melitus (DM) selama lebih dari 20 tahun juga menderita penyakit nefropati diabetik (ND). Penyakit DMT2 dan nefropati diabetik mengakibatkan tingginya angka morbiditas dan mortalitas. Akan tetapi, penatalaksanaan terapi yang tepat dapat menurunkan kejadian tersebut. Tujuan penelitian ini adalah untuk melakukan evaluasi penggunaan obat pada pasien rawat inap dengan penyakit DMT2 dan ND. Penelitian ini menggunakan metode cross-sectional dengan pengambilan data secara konkuren terhadap pasien rawat inap DMT2 dan ND pada periode Maret–Juni tahun 2017 di salah satu rumah sakit di Tasikmalaya, Indonesia. Empat puluh enam pasien diikutsertakan, dengan 25 pasien menderita penyakit DMT2 dan 21 pasien menderita ND. Dari hasil penelitian ini, diperoleh ketepatan penggunaan obat pada penderita DMT2 mencapai 100% sedangkan pada penderita ND mencapai 85,6%. Ketidaktepatan pemilihan obat meliputi pemilihan ketorolac, ranitidine, asam folat, amlodipine dan kalium klorida. Ketepatan dosis pada penderita DMT2 mencapai 100%, sedangkan pada penderita ND mencapai 92,1%. Ketidaktepatan dosis disebabkan oleh tidak adanya penyesuaian dosis dengan nilai estimated glomerulus filtration rate (eGFR) terhadap pasien. Selain itu, ditemukan potensi interaksi obat pada penderita ND dan DMT2 yang diklasifikasikan ke dalam kategori mayor (13,8%; 7,2%), moderat (64,1%; 58%), dan minor (22,1%; 34,8%), secara berturut-turut. Berdasarkan hasil penelitian, ditemukan ketidaktepatan pemilihan obat dan ketidaktepatan dosis pada pasien ND serta tingginya persentase potensi interaksi obat, terutama kategori moderat, pada kedua penyakit. Diperlukan optimalisasi peran apoteker sebagai bagian dari tim di ruangan pasien rawat inap untuk melakukan penerapan pemantauan terapi obat.

Kata kunci: Diabetes melitus tipe 2, evaluasi penggunaan obat, nefropati diabetik


Keywords


Drugs use evaluation, type 2 diabetes mellitus, diabetic nephropathy

Full Text:

PDF

References


Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman nasional pengendalian tuberkulosis. Katalog dalam Terbitan: Kementerian Kesehatan Nasional. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014.

World Health Organization. Global tuberculosis report 2016. World Health Organization; 2016.

Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesia tahun 2015. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016.

Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management. J Clin Exp Hepatol. 2013;3(1):37–49. doi: 10.1016/j.jceh.2012.12.001.

Arbex MA, Varella MDe C, Siqueira HR, Mello FA. Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 2: second-line drugs. J Bras Pneumol. 2010;36(5):641–56. doi: 10.1590/S1806-37132010000500017

Curry International Tuberculosis Center. Drug-resistant tuberculosis: A survival guide for clinicians, 2nd edition. Curry Int Tuberc Cent Calif Dep Public Heal. 2011;145–70.

Kurniawati F, Azhar S, Sulaiman S, Gillani SW. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. Int J Pharm Life Sci. 2012;3(1):1331–8.

Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, Shankar PR. A study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc. 2008;58(10):531–6.

Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22(2):83–94. doi: 10.1016/j.jsps.2013.02.003

Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81–95. doi: 10.1016/j.phrs.2006.11.001

Farazi A, Sofian M, Jabbariasl M, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat. 2014;412893:1–6. doi: 10.1155/2014/412893

Singla R, Sharma SK, Mohan A, Makharia G, Sreenivas V, Jha B, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132(7):81–6.

Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202. doi: 10.1111/j.1440-1746.2007.05207.x

Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. Hepatotoxicity of pyrazinamide: Cohort and case-control analyses. Am J Respir Crit Care Med. 2008;177(12):1391–6. doi: 10.1164/rccm.200802-355OC.

Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One. 2011; 6(7):1–7. doi: 10.1371/journal.pone.0021836.

Wiyati T, Irawati D, Budiyono I. Studi efek samping obat dan penanganannya pada pasien TB paru di Puskesmas Melong Asih, Cimahi. JSTFI Indones J Pharm Sci Technol. 2014;3(1):23–30.

Lin J, Sklar GE, Oh VM Sen, Li SC. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag. 2008;4(1):269–86. doi: 10.2147/TCRM.S1458

Nugrahaeni DK, Malik US. Analisis penyebab resistensi obat anti tuberkulosis. J Kesehat Masy. 2013;8(2):113–20.



Digital Object Identifier

DOI : https://doi.org/10.15416/ijcp.2018.7.4.243


Dimension Citation Metrics Badge

Refbacks

  • There are currently no refbacks.


 Indonesian Journal of Clinical Pharmacy is indexed by

        

  Creative Commons License

IJCP by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 

View My Stats